Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Platelet-rich fibrin matrix (PRFM) is an autologous biologic regenerative material used in dental surgery to treat chronic periodontitis and intraosseous defects. It is a second-generation platelet concentrate, often referred to as pure platelet-rich fibrin (P-PRF), prepared from the patient's own blood using a dual-spin centrifugation process with a thixotropic separator gel. This process creates a dense, cross-linked fibrin scaffold that traps concentrated viable platelets. These platelets provide a sustained release of intrinsic growth factors, such as PDGF, TGF-β, and VEGF, which stimulate fibroblast and osteoblast activity, promote angiogenesis, and facilitate bone fill and clinical attachment level gains in periodontal defects. The material is currently being evaluated by KLE Society's Institute of Dental Sciences in Phase 3 clinical trials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on platelet-rich fibrin matrix (KLE Society's Institute of Dental Sciences).